Brief: Jacobio Pharmaceuticals Says Kras G12c Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation
07/08/2023 15:56
Aug 7 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* KRAS G12C INHIBITOR JAB-21822 (GLECIRASIB) GRANTED
BREAKTHROUGH
THERAPY DESIGNATION BY CENTER FOR DRUG EVALUATION OF NMPA
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan